The rapid spread of SARS-CoV-2 led to the necessity of developing diagnostic tests for rapid virus detection. Many commercial platforms have appeared and have been approved for this purpose. In this study, 95 positive and 5 negative retrospective samples were analyzed by 4 different commercial RT-qPCR kits (TaqMan 2019nCoV Assay, Allplex™SARS-COV-2 Assay, FTD SARS-COV-2 Assay and qCOVID-19). The Hologic Aptima SARS-COV-2 and the Clart-COVID-19 system were also tested. serial dilutions of SARS-COV-2 standard control were included for sensitivity analysis. Among the qPCR tested qCOVID19 and Allplex™SARS-COV-2 Assay were both able to detect all the clinical samples included in the study. All four qPCR evaluated showed high sensitivity for samples with Ct<33. Clart-COVID-19 microarrays detected all samples and controls used in this study whereas Hologic Aptima Panther failed with one of the clinical samples. However, the main problem with this system was the number of invalidated samples despite avoiding the use of medium with guanidine isothiocyanate as recommended by the manufacturer. All the techniques tested were of value for SARS-CoV-2 detection.

SARS-CoV-2 的迅速传播导致有必要开发用于快速病毒检测的诊断测试。许多商业平台已经出现并被批准用于此目的。在这项研究中，使用 4 种不同的商业 RT-qPCR 试剂盒（TaqMan 2019nCoV Assay、Allplex™SARS-COV-2 Assay、FTD SARS-COV-2 Assay 和 qCOVID-19）分析了 95 个阳性和 5 个阴性回顾性样本。还测试了 Hologic Aptima SARS-COV-2 和 Clart-COVID-19 系统。SARS-COV-2 标准对照的连续稀释被纳入敏感性分析。在 qPCR 测试中，qCOVID19 和 Allplex™SARS-COV-2 Assay 都能够检测到研究中包含的所有临床样本。评估的所有四种 qPCR 均显示对 Ct < 33 的样品具有高灵敏度。Clart-COVID-19 微阵列检测了本研究中使用的所有样本和对照，而 Hologic Aptima Panther 未能检测到其中一个临床样本。然而，尽管按照制造商的建议避免使用异硫氰酸胍介质，但该系统的主要问题是无效样品的数量。所有测试的技术都对 SARS-CoV-2 检测有价值。